SUBSCRIBE: Print / eNewsletter
Current Era Means More AML Treatment Options for Elderly
Ahead of the 2014 ASH Annual Meeting & Exhibition we discuss current treatment strategies for elderly patients with acute myeloid leukemia.
Data Supports Ixazomib for Phase III Myeloma Trial
Early trial data support further evaluation of ixazomib combined with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Non-GCB DLBCL May Benefit Most From Immunochemotherapy
Non-germinal center B-cell-like DLBCL patients derived the most benefit from treatment with the immunochemotherapy regimen R-ACVBP compared with R-CHOP.
HDAC Inhibition With Decitabine Fails to Improve MDS, AML Outcomes
Adding the HDAC inhibitor valproic acid to decitabine did not improve outcomes in patients with myelodysplastic syndromes or acute myeloid leukemia.
Early Relapse After SCT Important for Prognosis in Multiple Myeloma
Patients who experienced early relapse of multiple myeloma after undergoing autologous stem cell transplantation had worse progression-free and overall survival.
New Targeted Therapies for CLL
In this interview we discuss the use of newly approved agents for chronic lymphocytic leukemia, next-generation therapies in the pipeline, and how the treatment of this type of leukemia has changed.
Three-Drug Combo Improved PFS in Relapsed, Refractory Myeloma
Panobinostat added to bortezomib/dexamethasone for treating relapsed/refractory multiple myeloma improved progression-free survival and complete response rates.
New Molecule Could Treat TKI-Resistant CML
STAT3 inhibition using a novel compound restored sensitivity to TKIs in CML cells that had shown resistance independent of BCR-ABL1 kinase activity.
Mutation in Cutaneous Lymphoma Linked to Poor Prognosis
A new study confirms that patients with primary cutaneous diffuse large B-cell lymphoma who have a MYD88 mutation have a shorter disease-specific survival.
Bortezomib Effective Induction Therapy for Multiple Myeloma Patients With Renal Failure
Treatment with bortezomib prior to autologous stem cell transplant resulted in superior outcomes in multiple myeloma patients with end-stage renal failure.